Adial pharmaceuticals announces research collaboration with uc san diego to advance purnovate's adenosine compounds as potential treatments for inflammatory diseases & disorders

Charlottesville, va., may 04, 2022 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), today announced that purnovate, inc., an adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the university of california san diego (uc san diego), a leading education and research university, and dr. peter ernst, dvm, phd, professor of pathology and an expert in the fields of immunology, inflammation and infectious disease, to further evaluate the company's proprietary adenosine analogs as a potential treatment for inflammatory diseases, including inflammatory bowel disease (ibd) and infectious diseases where a large immune response (i.e., cytokine storm) plays a significant role.
ADIL Ratings Summary
ADIL Quant Ranking